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Abstract Melanocortins are peptides with well-recognized
antiinflammatoryandneuroprotectiveactivity.Nodata are current-
ly available on melanocortin receptor-4 (MC4R) gene polymor-
phismsand tumors, includingglioblastomas (GBMs), or their rela-
tionshipwith radiotherapy or chemotherapy. The aim of this study
wastoevaluatethepossiblepredictive/prognosticroleof theMC4R
SNPsonGBMpatients.Fifty-fivepatientswithaprovendiagnosis
of GBM, treated with radiotherapy and temozolomide, were con-
secutively enrolled. MC4R gene SNPs (rs17782313, rs489693,
rs8087522, rs17700633) were analyzed by a validated TaqMan®
SNPgenotypingassays.Univariateandmultivariateanalyseswere
performed.AP<0.0125 (Bonferroni’s correction)wasconsidered
significant (Clinicaltrial.gov identifier NCT02458508). The
medianprogression-free survival (PFS)andmedianoverall surviv-
al (OS) of these patientswere 9.54 (95%CI 5.4–14.3)months and
24.9 (95% CI 17.8–34.6) months, respectively. The MC4R
rs489693AAgenotypewas significantly associatedwith a shorter
PFS and OS. Indeed, with regard to PFS, patients harboring the
rs489693AAgenotypehadamedianPFSof2.99monthswhereas
patientswithAC/CCgenotypeshadamedianPFSof10.82months
(P = 0.009). Interestingly, the rs489693 AA patients also had a
lower median OS as compared with the median OS of the
AC/CC genotypes (10.75 vs. 29.5 months, respectively,
P = 0.0001). This study suggests that the MC4R rs489693 AA
genotype is significantly associated with a shorter PFS and OS in
patients treated with radiotherapy and temozolomide. These find-
ings represent a relevant effort to identifynovel clinicalmarkers for
RT–CTtherapy inGBMtobevalidated in futurepharmacogenetic
clinical trials.
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Introduction
Glioblastoma (GBM) represents the most frequent malignant
primary brain tumor and, despite the latest advances recorded
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over the past decade, remains a lethal disease with a dismal
prognosis [1]. The treatment of glioblastomas remains difficult
in that no contemporary treatments are curative. The current
standard of care for newly diagnosed GBM was established in
2005, after the conclusion of the study leaded by Stupp [2] and
nowadays, upfront concomitant radiotherapy–chemotherapy
(RT–CT) with temozolomide (TMZ) represents the gold stan-
dard of care. Unfortunately, the recurrence rate after concomi-
tant RT-CTand the overall survival (OS) are still unsatisfactory;
indeed, 90% of patients experienced a disease relapse and the
median OS in clinical trial population was 15–18 months [3].
Despite important advances in the characterization of genomic
and microenvironment alterations in glioblastoma, targeted
agents have shown minimal efficacy in clinical trials to date,
and patient survival remains poor. Indeed, large placebo-
controlled randomized phase III trials aimed at targeting the
angiogenic phenotype of glioblastoma using bevacizumab (an
antivascular endothelial growth factor, VEGF) or cilengitide (an
integrin inhibitor) failed to show an improvement in overall
survival compared with the current standard of care [4].
Melanocortins are peptides with well-recognized
antiinflammatory and neuroprotective activity [5, 6]. Of the five
known melanocortin receptors, only subtype 4 is present in
astrocytes [7]. Melanocortin receptor-4 (MC4R) [8] has been
shown to mediate melanocortin effects on energy homeostasis
[9], inflammation [10], neuroprotection, and neurogenesis [6, 8,
11, 12] and, recently, to modulate astrocyte functions [7].
Recently, in experimental brain ischemia, treatment with
melanocortins acting at MC4Rs induced neural stem/
progenitor cell proliferation by triggering the canonical
wingless-type MMTV integration site (Wnt)-3A/β-catenin and
Sonic hedgehog (Shh) signaling pathway [13]. Moreover,
Caruso and colleagues demonstrated that MC4R activation by
α-melanocyte-stimulating hormone (α-MSH) protects astro-
cytes from apoptosis by decreasing caspase-3 activity and stim-
ulates proliferative effects in 7-day-old cultured astrocytes [7].
MC4R gene polymorphisms have emerged as new and
promising biomarkers for the prediction of weight gain in
patients treated with antipsychotic drugs [14]. Several inde-
pendent genome-wide association studies identified the poly-
morphism MC4R rs17782313 to be linked to increased body
weight and obesity [15], having shown an effect on bodymass
index (BMI) in different populations [16, 17]. Moreover, a
direct role in the interaction between fat mass- and obesity-
associated (FTO) and MC4R gene polymorphisms in breast
cancer development has been recently demonstrated [18]. On
the other hand, theMC4R rs17782313 polymorphism was not
related to endometrial cancer risk [19] although overweight
and obesity are strongly associated with this type of cancer.
Recently, no evidences were found supporting that individual
variants in MC4R gene are associated with risk of colorectal
cancer [20]. No data are currently available on MC4R gene
polymorphisms and GBMs or their relationship with the
success or failure to radio- or chemotherapy. The aim of this
study was to evaluate the possible prognostic/predictive role
of the MC4R SNPs on GBM therapy.
Patients and Methods
This was an exploratory, multicenter retrospective pharmacoge-
neticstudy.Fifty-fivepatientswithage≥18yearsanddiagnosisof
GBM were recruited, consecutively, and they were assessed for
the present pharmacogenetic study. The patients evaluated in this
study were treated with post-operative concomitant RT and CT.
RTwasdeliveredtosurgicalbedplusresidualdiseasewith2cmof
margin; the totaldosedeliveredwas60Gyin30fractions.CTwas
represented by TMZ that was administered at the dose of 75mg/
m2/dayduring theRT timeandof 150–200mg/m2/day for 5 days
every 28 days during 6–12 cycles, until disease progression or
toxicity occurrence. Disease relapse was assessed 1 month after
the end of concomitant RT–CT with a contrast magnetic reso-
nance imaging (MRI) and every 3 months for the first 3 years,
thenevery4months(ifapseudoprogressionwassuspected,anew
MRIwasperformedafter6weeks).Macdonaldcriteriawereused
to define disease control [21]. Each patient entering the study
signed the informed consent. The protocol was approved by the
ComitatoEtico diAreaVastaNordOvest (CEAVNO), Pisa, Italy
(CEAVNO prot. n. 17013; clinicaltrial.gov identifier
NCT02458508) and by the ethic committees of all participating
centers.
SNP Selection
The MC4R gene SNPs (rs17782313, rs489693, rs8087522,
rs17700633) included in our study (supplementaryTable 1)were
selected on the basis of four main considerations: (i) these SNPs
havebeendescribed tobeassociatedwithhumandiseases suchas
obesity and diabetes or with antipsychotic-induced weight gain
butnotwithcancer; (ii) only the rs17782313hasbeensignificant-
ly associated with risk of breast cancer [18] but not in the endo-
metrial [19] and colorectal cancer [20]; (iii) thus far, no genetic
analysis hasbeen reportedon the chosenMC4RSNPsandGBM;
and (iv) although for the chosen SNPs the phenotypic effects are
still undefined (i.e., the modulation of the gene expression or
activity of the receptor), we decided to include them in our pilot
research because of the possibility that some genotypes or haplo-
types could determine a statistical effect on patient’s survival.
Genotyping Analyses
Blood samples (3 ml) were collected in ethylenediaminetetra-
acetic acid (EDTA) tubes and stored at −80 °C. Germline
DNA extraction was performed using QIAamp DNA Blood
Mini Kit (Qiagen, Valencia, CA, USA). Allelic discrimination
of genes was performed using an ABI PRISM 7900 SDS
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(Applied Biosystems, Carlsbad, CA, USA) and with validated
TaqMan® SNP genotyping assays (i.e., C_32667060_10,
rs17782313; C_3058718_10, rs489693; C_29004626_10,
rs8087522; C_32666984_10, rs17700633; Applied
Biosystems). Polymerase chain reaction (PCR) reactions were
carried out according to the manufacturer’s protocol.
Genotyping was not performed until an adequate number of
events (>80% on study population) was reported in terms of
progression-free survival (PFS).
Statistical Analysis
The statistical analysis was performed by V. Simeon. All poly-
morphisms were analyzed for deviation from the Hardy–
Weinberg Equilibrium (HWE) through comparison between
observed allelic distributions with those expected from the
HWE by on χ2 test. Linkage disequilibrium (LD) between
markers in MC4R (n = 4) was analyzed using Haploview
software package [22]. The difference in PFS or OS between
genotype profiles was assessed with the log-rank test and the
Kaplan–Meier method to evaluate survival curves. A Cox
proportional hazards model, with the genotype profiles of
each individual polymorphism and the clinical and patholog-
ical patient characteristics individually correlatedwith the PFS
or OS, was used to calculate the adjusted hazards ratio (HR)
and the 95% confidence interval (95% CI). In these analyses,
we used Bonferroni’s correction and the P value <0.0125
(0.05/4 SNPs = 0.0125) was accepted as statistically signifi-
cant. The Kaplan–Meier and Cox proportional hazard analy-
ses were performed using the STATA package version 11.0
(StataCorp). Where an association was found to be significant
on univariate analyses, multivariate analysis was performed.
PFS was defined as the period of time from the beginning of
the RT–CT treatment to the first observation of disease pro-
gression as above described, or death from any cause. OS was
calculated from the date of the diagnosis to the date of death/
lost to follow-up. Due to the small sample size in OS data,
multivariate analysis was restricted to only three variables.
Decision on best model was performed calculating Bayesian
Information Criterion (BIC) [23].
PHASE software v2.1 [24] was used to perform haplotype
analysis for MC4R regions separately. Only common haplo-
types with a frequency ≥5% were included in Cox survival
analysis. The most common haplotype was used as the refer-
ence and were provided hazard ratios (HR) for a given haplo-
type relative to reference haplotype.
Results
Fifty-five patients with diagnosis of GBM were enrolled into
the study and genotypized for MC4R SNPs. Details about
genotypes and allele frequencies of all SNPs in the entire
population are reported in supplementary Table 1; all the
SNPs were in HWE. The clinical characteristics of the 55
patients are summarized in Table 1. All patients were clinical-
ly assessable for PFS and OS. The PFS of these patients was
9.54 months (95% CI 5.4–14.3), whereas the OS resulted
24.9 months (95% CI 17.8–34.6). The hematological toxicity
(i.e., leucopenia and thrombocytopenia) was recorded during
the RT–CT treatment and reported in supplementary Table 2.
The univariate Cox regression analysis showed the role of
the age at diagnosis (HR = 1.03; P = 0.035) and of the frontal
localization (HR = 0.46; P = 0.028) of the disease in deter-
mining the PFS of this group of patients (supplementary
Table 3). The same univariate analysis confirmed the role of
the frontal lobe site (HR = 0.38; P = 0.026) of the disease in
determining the OS with the addition of performance status
(HR = 0.98; P = 0.03) and the administered lines of chemo-
therapy (HR = 0.6; P = 0.031) (supplementary Table 4).
Table 1 Characteristics of patients
Characteristics
Sex, n (%)
Male 27 (49.1)
Female 28 (50.9)
Weight
Mean ± SD 73.3 ± 12.9
Median (range) 72.5 (52–103)
Age at diagnosis
Mean ± SD 56.6 ± 12.4
Median (range) 58 (24–80)
Body mass index (BMI)
Mean ± SD 25.1 ± 3.97
Median (range) 25 (21.6–27.8)
Previous radiotherapy, n (%)
No 36 (65.45)
Yes 16 (29.09)
Unknown 3 (5.45)
Lines of chemotherapy, n (%)
1 25 (45.45)
2 16 (29.09)
3 10 (18.18)
4 3 (5.45)
Unknown 1 (1.82)
Frontal lobe site, n (%)
No 34 (61.82)
Yes 17 (30.91)
Unknown 4 (7.27)
Performance status
Mean ± SD 78.9 ± 19.7
Median (range) 80 (30–100)
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A statistically significant association with PFS in univariate
Cox regression analysis, either under an additive, dominant, or
recessive model (as illustrated in Table 2), was found with
MC4R rs489693 that reaches the significance threshold in both
the additive (P = 0.012) and dominant models (P = 0.009).
Indeed, the PFS values of MC4R rs489693 AA, CA, and CC
patients were 2.99 (95% CI 2.3–4.5), 9.77 (95% CI 5.1–22.7),
and 10.82 (95% CI 5.4–17.8) months, respectively (Fig. 1a),
whereas the PFS of CC/CA genotypes was 10.82 (95% CI
5.7–15.8) months vs. 2.99 (95% CI 2.3–4.5) months of the
harboring AA patients (Fig. 1b). Interestingly, the same SNP
maintained the same statistically significant association with
OS (n = 53) in univariate Cox regression analysis, either under
an additive (P = 0.0001) or a dominant (P = 0.0001) model as
shown in Table 3. Indeed, the OS values of MC4R rs489693
AA, CA, andCC patients were 10.75 (95%CI 7.4–12.5), 25.75
(95% CI 13.5–57.3), and 34.1 (95% CI 17.7–73.2) months,
respectively (Fig. 1c), whereas the OS of CC/CA genotypes
was 29.5 (95% CI 22.6–40.1) months vs. 10.75 (95% CI
7.4–12.5) months of the harboring AA patients (Fig. 1d).
Furthermore, the haplotype analysis of the MC4R genetic re-
gion (supplementary Fig. 1a) did not reveal any significant
association in univariate Cox regression model and Kaplan–
Meier PFS (n = 55; supplementary Fig. 2b) and OS (n = 53;
supplementary Fig. 1c) curves.
Notably, the multivariate analyses adjusted for the age at the
diagnosis, frontal lobe localization, and lines of chemotherapy
revealed that the MC4R rs489693 AA genotype was the most
powerful single factor associated with the PFS (HR = 3.45 and
P = 0.018 for the additive model; HR = 3.14 and P = 0.021 for
the dominant model), as described in Table 4. The best models
in multivariate analyses with OS data, selected with BIC value
(supplementary Table 5), were both additive and dominant
models of MC4R rs489693 (HR = 6.1 and P = 0.004 for the
additive model; HR = 4.9 and P = 0.006 for the dominant
model) adjusted for performance status and frontal lobe locali-
zation (Table 5). The one with the dominant model shows the
lowest BIC value with positive to strong evidence to be pre-
ferred against the others.
No association betweenMC4R SNPs and weight of patients
at the diagnosis was found (data not shown), as well as between
MC4R SNPs and localization of the disease or hematological
toxicities (data not shown). Although analyzed in a small subset
of patients (n = 27) with available tumor tissues, as expected, the
tumor O6-methylguanine-DNA methyltransferase (MGMT)
methylation significantly increase the PFS (15.8 vs. 5.13months,
P = 0.02; n = 27; supplementary Fig. 2a) and, even though it did
not reach a statistical significance, also the OS (25.9 vs.
17.8 months, P = 0.25; n = 27; supplementary Fig. 2b).
Discussion
The present study describes, for the first time, the association
betweenMC4R polymorphisms and survival of GBM patients
under RT–CT regimen that consists of TMZ and concomitant
RT (60 Gy). In this regard, the individual genetic traits of
patients may have a role in the response to chemotherapy or
to radio-therapeutic strategies in GBM. Indeed, the TMZ-
treated GBM patients harboring the T allele of the MGMT
promoter SNP rs16906252 have shown a better survival, in-
dependently of the tumor methylation status [25]. However,
with the exception of the establish role of MGMTmethylation
[26], there are currently no validated genetic biomarkers to
predict or to monitor favorable clinical response or resistance
to concomitant radio- and TMZ therapies [27]. Therefore,
Table 2 Association between each MC4R polymorphism and PFS (univariate Cox regression model)
ID Additive model Dominant model Recessive model
Genotype N HR P 95% CI Genotype N HR P 95% CI Genotype N HR P 95% CI
rs17782313 TT 30 1 – – TT/TC 53 1 – – TT 30 1 – –
TC 23 1.33 0.35 0.73–2.42 TC/CC 25 1.4 0.26 0.78–2.52
CC 2 3.31 0.11 0.76–14.4 CC 2 2.92 0.14 0.69–12.4
rs489693 CC 30 1 – – CC/CA 49 1 – – CC 30 1 – –
CA 19 0.97 0.93 0.51–1.85 CA/AA 25 1.2 0.53 0.67–2.17
AA 6 3.26 0.012 1.29–8.22 AA 6 3.29 0.009 1.34–8.04
rs8087522 GG 32 1 – – GG/GA 52 1 – – GG 32 1 – –
GA 20 0.8 0.5 0.43–1.5 GA/AA 23 0.78 0.44 0.43–1.44
AA 3 0.66 0.57 0.16–2.8 AA 3 0.72 0.66 0.18–3
rs17700633 GG 35 1 – – GG/GA 54 1 – – GG 35 1 – –
GA 19 1.82 0.055 0.98–3.38 GA/AA 20 1.54 0.16 0.84–2.83
AA 1 a 1 a AA 1 a 1 a
A P value <0.0125 was defined as statistically significant (Bonferroni’s correction)
a The value was not determined because of the occurrence of only one AA case
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Fig. 1 Kaplan–Meier curves for progression-free survival (PFS) of
patients harboring a) MC4R rs489693 CC, CA, and AA genotypes and
b)MC4R rs489693 CC/CA and AA genotypes. Kaplan–Meier curves for
overall survival (OS) of patients harboring c) MC4R rs489693 CC, CA,
and AA genotypes and d) MC4R rs489693 CC/CA and AA genotypes.
95% CI 95% confidence interval
Table 3 Association between each MC4R polymorphism and OS (univariate Cox regression model)
ID Additive model Dominant model Recessive model
Genotype N HR P 95% CI Genotype N HR P 95% CI Genotype N HR P 95% CI
rs17782313 TT 29 1 – – TT/TC 51 1 – – TT 29 1 – –
TC 22 1.94 0.075 0.94–3.9 TC/CC 24 2.08 0.041 1.03–4.2
CC 2 6.1 0.022 1.3–28.7 CC 2 4.47 0.049 1.01–19.9
rs489693 CC 29 1 – – CC/CA 47 1 – – CC 29 1 – –
CA 18 1.08 0.855 0.5–2.4 CA/AA 24 1.5 0.24 0.75–3.04
AA 6 7.02 0.0001 2.44–20.2 AA 6 6.8 0.0001 2.5–18.6
rs8087522 GG 30 1 – – GG/GA 50 1 – – GG 30 1 – –
GA 20 0.79 0.53 0.4–1.65 GA/AA 23 0.84 0.61 0.42–1.7
AA 3 1.23 0.78 0.3–5.3 AA 3 1.35 0.69 0.32–5.7
rs17700633 GG 34 1 – – GG/GA 52 1 – – GG 34 1 – –
GA 18 1.44 0.36 0.66–3.15 GA/AA 19 1.25 0.58 0.6–2.7
AA 1 a 1 a AA 1 a 1 a
A P value <0.0125 was defined as statistically significant (Bonferroni’s correction)
a The value was not determined because of the occurrence of only one AA case
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efforts to identify new genetic biomarkers for non-invasive
detection of treatment success are an important component
of GBM research to improve the overall survival and quality
of life of GBM patients. In this perspective, a recent study has
associated the suppressor of Lin-12-like (Caenorhabditis
elegans) (SEL1L) rs12435998 C allele with a prolonged OS
(18 vs. 13 months, P = 0.011) and a better response to TMZ-
based radio–chemotherapy (i.e., Stupp’s protocol) in 55 GBM
patients [28]. Moreover, Di Stefano and colleagues have dem-
onstrated that the VEGF-A rs2010963 CC genotype is associ-
ated with longer PFS and higher risk of vascular events in
patients with recurrent GBM if treated with bevacizumab,
but not when treated with the TMZ [29]. Here, we report the
impact of commonly reported MC4R sequence variants, usu-
ally described in the gain of weight during antipsychotic
therapy [30–33], in relation to clinical survival following
RT–CT concomitant treatment. In particular, we decided to
test the hypothesis that, given the association between
MC4R with prevention of astrocyte apoptosis [7], induction
of neural stem/progenitor cell proliferation in brain hypoxia
[11], neuroprotection, and antiinflammatory activity [6], the
MC4R SNPs could have a possible direct role in the modula-
tion of the cytotoxic, and thus therapeutic, effects of radiother-
apy and TMZ on GBM or they could influence the prognosis
of the disease through their effect on patient’s tumors.
Our results clearly show that there was a robust statistical
association between the MC4R rs489693 AA genotype and a
shorter progression-free survival of patients treated with the
combination of RT and TMZ. Moreover, this association was
maintained also in the overall survival, indicating a statistical
disadvantage for patients harboring this particular genotype if
treated with this standard therapeutic approach for GBM. To
our knowledge, no other data are currently available linking
polymorphisms ofMC4R gene and therapeutic efficacy or tox-
icity of any type of cancer, including GBM, thus representing a
novel, although preliminary, discovery in the field that should
be confirmed bywider and prospective pharmacogenetic trials.
One of the hallmarks of GBM is represented by the pres-
ence of necrotic areas within the tumor mass, and thus, these
areas are commonly characterized by severe hypoxia. Indeed,
the hypoxia-inducible factor-1 alpha (HIF-1α) has been re-
ported to play a pivotal role in GBM development and pro-
gression because of its characteristic to induce the upregula-
tion of numerous genes such as VEGF [34]. Thus, tumor cells
survive acquiring molecular (e.g., VEGF secretion) or genetic
changes as the result of the inadequate supply of O2 and nu-
trients [35, 36]. Indeed, one of the main factors responsible for
GBM treatment failure is this hypoxia, while causing apopto-
tic and necrotic death of normal cells permits to neoplastic
cells to develop defense mechanisms [37]. Moreover, several
studies have demonstrated that glioma and glioblastoma cells
exhibit important resistance to apoptosis after exposure to ion-
izing radiation [38], as well as the key role of the expression
status of B cell lymphoma-2 (Bcl-2) family proteins that are
fundamental for the activation of the apoptosis pathway in
GBM after TMZ administration, even in cancer stem cells
[39, 40]. Besides, the antiapoptotic mechanisms of resistance
[41] and also the activation of specific pathways such as Wnt-
3A/β catenin, Shh, and Notch have been implicated in tumor
radio- and chemoresistance [42, 43].
MC4Rs are expressed predominantly in the brain,
both on neurons and astrocytes, but they were also de-
tected in adipose tissue and in human skin melanocytes
[44]. Although the brain distribution of the MC4 recep-
tor in mice and rats has been extensively studied [44],
the mapping of brain human MC4R is still an open
field. Moreover, no data are available on MC4R gene
and protein expression in GBM or other cancer cells,
Table 4 Multivariate Cox regression model of PFS
HR P 95% CI
Age at diagnosis 1.01 0.311 0.98–1.04
Lines of chemotherapy 0.82 0.311 0.55–1.2
Frontal lobe site 0.46 0.058 0.2–1.03
rs489693_additive
CC 1 – –
CA 1.25 0.558 0.6–2.6
AA 3.45 0.018 1.23–9.6
Age at diagnosis 1.01 0.291 0.98–1.04
Lines of chemotherapy 0.81 0.297 0.55–1.2
Frontal lobe site 0.50 0.07 0.24–1.06
rs489693_dominant
CC/CA 1
AA 3.14 0.021 1.2–8.3
Lines of chemotherapy is represented as an ordinal variable
HR hazard ratio, CI confidence interval
Table 5 Multivariate Cox regression model of OS
HR P 95% CI
Performance status 0.99 0.39 0.97–1.01
Frontal lobe site 0.42 0.052 0.17–1.01
rs489693_dominant
CC/CA 1
AA 4.9 0.006 1.6–15.8
Performance status 0.99 0.37 0.97–1.01
Frontal lobe site 0.38 0.035 0.15–0.94
rs489693_additive
CC 1
CA 1.64 0.28 0.7–4.02
AA 6.1 0.004 1.76–21.2
HR hazard ratio, CI confidence interval
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although our group has demonstrated the presence of
functional MC4Rs in at least two human GBM cell
lines (Bocci G., unpublished data). Although at a first
glance the MC4R functions have been described in
completely different areas such the control of weight,
it is not surprising that MC4R may share more than a
simple statistical connection with the success of RT-CT
therapy and/or prolonged survival in GBM. In fact, it
has been demonstrated that MC4R signaling can stimu-
late both the survival of astrocytes, by decreasing
caspase-3 activity and the expression of Bcl-2-
associated X protein (Bax) and by increasing the ex-
pression of Bcl-2 [45], and the proliferation of neural
stem/progenitor cell under hypoxic conditions, by trig-
gering the canonical Wnt-3A/β-catenin and Shh signal-
ing pathway [13]. Moreover, in an animal model of
cerebral ischemia and Alzheimer’s disease, the chronic
treatment with the melanocortin analog [Nle(4), D-
Phe(7)]α-melanocyte-stimulating hormone (NDP-α-
MSH), an MC4R agonist, significantly reduced neuron
death [6, 11, 46, 47]. This neuroprotection involved
Bcl-2 upregulation and the decreased expression of
pro-apoptotic Bax and caspase-3 activation [6, 46], as
also described in a model of traumatic brain injury [48].
Moreover, proliferative effects of NDP-α-MSH have
been recently reported in 7-day-old cultured astrocytes
[7]. Therefore, it might be plausible that the MC4R
rs489693 AA genetic background, although phenotypi-
cally still unknown, may be responsible, in part, for
pro-survival and antiapoptotic signals to cancer cells in
hypoxic conditions or after radio-chemotherapy-induced
damages, determining the shorter PFS and OS in these
GBM cancer patients. Conversely, in patients with a
more favorable genetic profile, the MC4R survival sig-
nal to cancer cells due to the different genotypes may
be reduced and, in the presence of RT and TMZ, tumor
cells are less capable to proliferate or survive.
This study recruited, consecutively, 55 patients treated
with RT and TMZ at our institution and other centers. An
obvious limitation of this work is that the association be-
tween the PFS or OS and the MC4R genotype was
assessed on a limited number of patients. Thus, initial data
from pilot studies should be scrutinized with the most
accurate statistical correction [49], as in the present study,
where we applied a strict Bonferroni’s correction to our
data in order to avoid the risk of false-positive associa-
tions. Moreover, there are also some limitations with our
findings in regard to the role of MC4R rs489693 as phar-
macogenetic marker, which could be also a prognostic
factor. Indeed, it is possible that the MC4R rs489693 AA
genotype may be associated with a worse disease out-
come, independently from the efficacy of the administra-
tion of RT and TMZ. However, the importance of
pharmacogenetic pilot studies is that they may open new
areas of research, such as, in this case, the possible role of
MC4R in the GBM resistance to standard therapy.
Furthermore, they could guide the planning of future, ran-
domized, controlled, and multiinstitutional pharmacoge-
netic studies.
In conclusion, our pilot study suggests that the MC4R
rs489693 AA genotype is significantly associated with a
shorter PFS and OS in patients treated with a combined RT
and TMZ schedule. These findings represent a relevant effort
to identify novel clinical markers for RT–CT therapy in GBM,
which can be applied in future phase III clinical trials.
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Supplementary Figure S1 
Haploview Linkage Disequilibrium Plots and Haplotype analysis in 
PHASE of MC4R gene region (A). Linkage disequilibrium was measured 
using r2 in MC4R gene region. Diamonds are white if r2 = 0, varying 
shades of grey if 0 < r2 < 1, and are black if r2 = 1. An haplotype 
analysis was performed using PHASE. Uncommon haplotypes (< 5%) 
were highlighted in red. None of the haplotype is significantly 
associated with PFS (B) and OS (C) survival in Kaplan Meier analysis 
for MC4R as well as in the univariate Cox model . 
P
ro
gr
es
si
o
n
 F
re
e 
Su
rv
iv
al
 (
%
) 
Months 
Median: 11.15 months 
95%CI 6.3-15.8  
Median: 7  months 
95%CI 4.7-13.7  
Median: 4.6  months 
95%CI 2.8- 
TC 
CA 
TA 
Median: 2.9  months 
95%CI 2.9- 
CC 
O
ve
ra
ll 
Su
rv
iv
al
 (
%
) 
Months 
Median: 29. 5 months 
95%CI 22.6-39.6  
Median: 17.8  months 
95%CI 12.7-25.7  
Median: 12.3  months 
95%CI 7.4- 
TC 
CA 
TA 
Median: 5.3  months 
95%CI 5.3- 
CC 
MC4R haplotypes HR 95%CI p 
TC (reference) 1 - - 
CA 1.35 0.83-2.2 0.23 
TA 1.8 0.78-4.2 0.17 
CC 3.3 0.78-13.6 0.1 
MC4R haplotypes HR 95%CI p 
TC (reference) 1 - - 
CA 1.89 1.08-3.3 0.03 
TA 1.87 0.74-4.7 0.19 
CC 7.3 0.95-56.3 0.06 
Supplementary Figure S2 
PFS (A) and OS (B) survival in Kaplan Meier analysis for MGMT methylation as well as in the univariate Cox model . 
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 Supplementary table 1 - Polymorphisms, genotypes, allele frequencies and Hardy-
Weinberg Equilibrium (HWE) 
ID Gene 
Genotype Allele 
HWE p-value 
G n % A n % 
rs17782313 MC4R 
TT 30 54.55 T 83 0.75 0.48 
TC 23 41.82 C 27 0.25 
 
CC 2 3.64         
rs489693 MC4R 
CC 30 54.55 C 79 0.72 0.32 
CA 19 34.55 A 31 0.28 
 
AA 6 10.91         
rs8087522 MC4R 
GG 32 58.18 G 84 0.76 1 
GA 20 36.36 A 26 0.24 
 
AA 3 5.45         
rs17700633 MC4R 
GG 35 63.64 G 89 0.81 0.66 
GA 19 34.55 A 21 0.19 
 
AA 1 1.82         
 
 Supplementary table 2. Hematological toxicities  
leucopenia grade, n (%) 
 0 8 (14.55) 
1 17 (30.91) 
2 10 (18.18) 
3 2 (3.64) 
4 1 (1.82) 
Unknown 17 (30.91) 
leucopenia, n (%) 
 0-1-2 35 (63.64) 
3-4 3 (5.45) 
Unknown 17 (30.91) 
thrombocytopenia grade, n (%) 
 0 1 (1.82) 
1 11 (20.00) 
2 10 (18.18) 
3 10 (18.18) 
4 6 (10.91) 
Unknown 17 (30.91) 
thrombocytopenia, n (%) 
 0-1-2 22 (40.00) 
3-4 16 (29.09) 
Unknown 17 (30.91) 
 
 Supplementary table 3. Association between clinical and pathological 
characteristics with PFS in the whole study cohort 
 
HR p 95% CI 
Weight 1.0002 0.988 0.98 - 1.02 
Sex 1.008 0.98 0.56 - 1.8 
Age at diagnosis 1.03 0.035 1.002 - 1.05 
Previous radiotherapy 0.78 0.46 0.4 - 1.5 
leucopenia, grade 0.89 0.52 0.63 - 1.26 
leucopenia 0.79 0.7 0.24 - 2.6 
thrombocytopenia, grade 0.88 0.44 0.64 - 1.2 
thrombocytopenia 1.08 0.82 0.55 - 2.15 
Performance Status 0.98 0.226 0.97 - 1.006 
Lines of chemotherapy 0.72 0.057 0.51 - 1.01 
Lines of chemotherapy, n 
   
1 (ref) 1 - - 
2 0.89 0.75 0.46 - 1.76 
3 0.46 0.088 0.19 - 1.13 
4 0.4 0.23 0.09 - 1.75 
Frontal lobe site 0.46 0.028 0.23 - 0.92 
HR, hazard ratio; CI, confidence interval. Leucopenia and thrombocypenia 
represents the difference between patients with ≤2 (reference) and >2, or where 
specified ‘grade’ is represented as ordinal value; Lines of chemotherapy is 
represented as an ordinal variable or using Line 1 as reference 
 
 Supplementary table 4. Association between clinical and pathological 
characteristics with OS in the whole study cohort 
 
HR p 95% CI 
Weight 0.99 0.75 0.97 - 1.02 
Sex 0.82 0.57 0.4 - 1.64 
Age at diagnosis 1.03 0.06 0.99 - 1.06 
Previous radiotherapy 0.78 0.53 0.36 - 1.7 
leucopenia, grade 0.93 0.74 0.61 - 1.4 
leucopenia 1.38 0.6 0.41 - 4.7 
thrombocytopenia, grade 1.06 0.75 0.73 - 1.54 
thrombocytopenia 1.12 0.79 0.5 - 2.5 
Performance Status 0.98 0.03 0.96 - 0.99 
Lines of chemotherapy 0.6 0.031 0.38 - 0.95 
Lines of chemotherapy, n 
   
1 (ref) 1 - - 
2 0.76 0.48 0.34 - 1.65 
3 0.26 0.036 0.07 - 0.92 
4 0.37 0.333 0.05 - 2.8 
Frontal lobe site 0.38 0.026 0.16 - 0.89 
HR, hazard ratio; CI, confidence interval. Leucopenia and thrombocytopenia 
represents the difference between patients with ≤2 (reference) and >2, or where 
specified ‘grade’ is represented as ordinal value. Lines of chemotherapy is 
represented as an ordinal variable or using Line 1 as reference. 
 
 
Supplementary table 5. Model selection using Bayesian Information Criterion (BIC) 
Age at 
diagnosis 
Performance 
Status 
Lines of 
chemotherapy 
Frontal 
lobe site 
rs489693 
additive 
rs489693 
dominant BIC ΔBIC 
 
x 
 
x 
 
x 166.04 Δ 
 
x 
 
x x 
 
168.60 2.56 
x x 
 
x 
  
169.29 3.25 
 
x x x 
  
170.54 4.50 
x x 
   
x 176.55 10.51 
 
x x 
  
x 178.58 12.54 
x x x 
   
179.39 13.35 
x x 
  
x 
 
180.21 14.17 
  
x x 
 
x 180.78 14.74 
 
x x 
 
x 
 
182.34 16.30 
  
x x x 
 
184.09 18.05 
x 
 
x x 
  
190.19 24.15 
x 
  
x 
 
x 191.44 25.40 
x 
 
x 
  
x 192.12 26.08 
x 
  
x x 
 
194.24 28.20 
x 
 
x 
 
x 
 
196.05 30.01 
Lines of chemotherapy is represented as an ordinal variable or using Line 1 as reference. 
Each line represent a different combination. The Bayesian Information Criterion (BIC) was calculated for 
each model and the one with the lowest BIC is preferred. The strength of the evidence against the model 
with the higher BIC value can be summarized as follows: ΔBIC - 0 to 2, not worth more than a bare mention; 
ΔBIC - 2 to 6, positive evidence; ΔBIC - 6 to 10, strong evidence; ΔBIC - >10, very strong evidence 
